

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement appears for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for the securities of the Company.



Boill Healthcare Holdings Limited

保集健康控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1246)

DELAY IN DESPATCH OF CIRCULAR

Reference is made to the announcement of Boill Healthcare Holdings Limited (the “**Company**”) dated 24 July 2020 (the “**Announcement**”). Capitalised terms used herein shall have the same meanings as those defined in the Announcement unless the context requires otherwise.

Pursuant to Rule 8.2 of the Takeovers Code, a circular (the “**Circular**”) containing, among other matters, (i) further details of the Share Consolidation and the Change in Board Lot Size; (ii) further details of the Acquisition; (iii) further information about the Whitewash Waiver; (iv) a letter of recommendation of the Independent Board Committee in relation to the Acquisition; (v) a letter of recommendation of the Takeovers Code Independent Board Committee in relation to the Acquisition and the Whitewash Waiver; (vi) a letter of advice from the Independent Financial Adviser to the Independent Board Committee, the Takeovers Code Independent Board Committee and the Independent Shareholders in relation to the Acquisition and the Whitewash Waiver; (vii) the financial information of the Group, the Target Group and the Project Company; (viii) the unaudited pro forma financial information of the Enlarged Group upon Completion; (ix) the property valuation reports; (x) the notice convening the EGM; and (xi) other information as required under the Listing Rules and the Takeovers Code is required to be despatched to the Shareholders within 21 days from the date of the Announcement, i.e. on or before 14 August 2020.

As additional time is required for the Company to finalise certain information in the Circular, an application has been made to the Executive pursuant to Rule 8.2 of the Takeovers Code for, and the Executive has granted its consent to an extension of time for the despatch of the Circular to the Shareholders to a date falling on or before 25 August 2020.

WARNING

As the Share Consolidation and Completion is conditional upon fulfillment or waiver (where applicable) of a number of conditions precedent, the Share Consolidation and the Acquisition may or may not proceed, respectively. In addition, the Whitewash Waiver may or may not be granted.

Shareholders and potential investors are urged to exercise extreme caution when dealing in the Shares. If they are in any doubt, they should consult their professional advisers.

By Order of the Board
Boill Healthcare Holdings Limited
Dai Dong Xing
Executive Director and Chairman

Hong Kong, 13 August 2020

As at the date of this announcement, the Company has (i) two executive Directors, namely Mr. Dai Dong Xing and Mr. Zhang Sheng Hai; (ii) one non-executive Director, namely Mr. Chui Kwong Kau; and (iii) three independent non-executive Directors, namely Mr. Chan Chi Keung Billy, Mr. Xu Liang Wei and Mr. Wang Zhe.

The Directors jointly and severally accept full responsibility for the accuracy of the information contained in this announcement and confirm, having made all reasonable inquiries, that to the best of their knowledge, opinions expressed in this announcement have been arrived at after due and careful consideration and there are no other facts not contained in this announcement, the omission of which would make any statement in this announcement misleading.